Mesenteric vasoconstrictor response to 5-hydroxytryptamine in the in situ blood autoperfused rat mesentery:: involvement of 5-HT2B and/or 5-HT2C receptor activation

被引:20
|
作者
Fernández, MD [1 ]
Morán, A [1 ]
Martín, ML [1 ]
San Román, L [1 ]
机构
[1] Univ Salamanca, Fac Farm, Dept Fisiol & Farmacol, Lab Farmacognosia & Farmacol, E-37007 Salamanca, Spain
关键词
5-HT; (5-hydroxytryptamine; serotonin); alpha-methyl-5-hydroxytryptamine; vasoconstrictor effect; mesenteric blood flow; 5-HT2B/2C receptor;
D O I
10.1016/S0014-2999(00)00444-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Using a number of agonist and antagonist compounds, we attempted to characterize the responses and receptors involved in the effects of 5-hydroxytryptamine (5-HT) in the in situ blood perfused rat mesentery. An intra-arterial (i.a.) bolus injection of 5-HT increased mesenteric perfusion pressure in a dose-dependent way but did not change the systemic blood pressure. The selective 5-HT2 receptor agonists alpha-methyl-5-HT, 1-(3-chlorophenyl)piperazine dihydrochloride (m-CPP) and (+/-)-1-(4-iodo-2,5-dimethoxyphenyl)-2-aminopropane hydrochloride (DOI), caused a local vasoconstrictor effect in the autoperfused vascular mesenteric bed. Intra-arterial injection of 5-carboxamidotryptamine (5-CT) and 1-(m-chlorophenyl)-biguanide (m-CPBG) did not modify the mesenteric perfusion pressure. The vasoconstrictor effect elicited by 5-HT and alpha-methyl-5-HT was significantly decreased by ritanserin and by a selective 5-HT2B/2C receptor antagonist, N-3-pyridinyl-3,5-dihydro-5-methyl-benzo[1,2-b:4,5-b']dipyrrole-1(2H)-carboxamide hydrochloride (SB 206553), but was not modified by prazosin, propranolol. indomethacin or enalapril pretreatment. Our data suggest that the vasoconstrictor serotonergic response induced in the in situ autoperfused rat mesenteric vascular bed is mainly mediated by activation of 5-HT2B and/or 5-HT2C receptors. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:221 / 227
页数:7
相关论文
共 50 条
  • [31] 5-HT2C receptor antagonists:: Potential in schizophrenia
    Wood, MD
    Heidbreder, C
    Reavill, C
    Ashby, CR
    Middlemiss, DN
    DRUG DEVELOPMENT RESEARCH, 2001, 54 (02) : 88 - 94
  • [32] The 5-HT2C receptor as a target for mood disorders
    Serretti, A
    Artioli, P
    De Ronchi, D
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2004, 8 (01) : 15 - 23
  • [33] Roles of the 5-HT2C receptor on zebrafish sociality
    Moura, Layana Aquino de
    Pyterson, Maryana Pereira
    Pimentel, Ana Flavia Nogueira
    Araujo, Fernanda
    Souza, Loanne Valeria Xavier Bruce de
    Mendes, Caio Henrique Moura
    Costa, Bruna Patricia Dutra
    Siqueira-Silva, Diogenes Henrique de
    Maximino, Monica Lima-
    Maximino, Caio
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2023, 125
  • [34] Activating mutations of the serotonin 5-HT2C receptor
    HerrickDavis, K
    Egan, C
    Teitler, M
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 (03) : 1138 - 1144
  • [35] Localization of the gene for the human serotonin 5-HT2B receptor to chromosome 2
    Horton, YM
    Lubbert, H
    Houslay, MD
    MOLECULAR MEMBRANE BIOLOGY, 1996, 13 (01) : 29 - 31
  • [36] The Bulky N(6) Substituent of Cabergoline Is Responsible for Agonism of This Drug at 5-Hydroxytryptamine (5-HT)2A and 5-HT2B Receptors and Thus Is a Determinant of Valvular Heart Disease
    Kekewska, Alexandra
    Huebner, Harald
    Gmeiner, Peter
    Pertz, Heinz H.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 338 (01) : 381 - 391
  • [37] In vitro evidence that 5-hydroxytryptamine increases efflux of glial glutamate via 5-HT2A receptor activation
    Meller, R
    Harrison, PJ
    Elliott, JM
    Sharp, T
    JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 67 (03) : 399 - 405
  • [38] EVIDENCE THAT 5-HT(2)-RECEPTORS PREDOMINANTLY MEDIATE THE CONTRACTION OF THE RAT BASILAR ARTERY TO 5-HYDROXYTRYPTAMINE
    DECKERT, V
    ANGUS, JA
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 221 (01) : 17 - 25
  • [39] Modulation of 5-HT4 receptor function in the rat isolated ileum by fluoxetine:: the involvement of endogenous 5-hydroxytryptamine
    Tuladhar, BR
    Costall, B
    Naylor, RJ
    BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (01) : 150 - 156
  • [40] (1R, 3S)-(-)-Trans-PAT: A novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity
    Booth, Raymond G.
    Fang, Lijuan
    Huang, Yingsu
    Wilczynski, Andrzej
    Sivendran, Sashikala
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 615 (1-3) : 1 - 9